elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q47151168-1C7E8E31-5246-4FCC-9FBD-60DD249268EE
Q47151168-1C7E8E31-5246-4FCC-9FBD-60DD249268EE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47151168-1C7E8E31-5246-4FCC-9FBD-60DD249268EE
Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors.
P2860
Q47151168-1C7E8E31-5246-4FCC-9FBD-60DD249268EE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47151168-1C7E8E31-5246-4FCC-9FBD-60DD249268EE
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
a8cb5ab8bc12ec9b6813a3e3c654df2246d9e00f
P2860
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.